GE HealthCare Technologies Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
GE HealthCare reported Q3 2026 revenues of $5.5B (up 7.2% YoY, 6.2% organic), with diluted EPS of $1.36 (up 39.1%) and adjusted EPS of $1.34 (up 25.1%). Net income margin expanded to 11.1% (from 8.7%), and adjusted EBIT margin to 16.6% (from 14.8%). The company raised full-year 2026 organic revenue growth guidance to ~4.0% (from 3.0-4.0%) and adjusted EPS to $4.95-$5.05 (from $4.80-$5.00). In October 2026, GE HealthCare announced the acquisition of SOFIE Biosciences from Trilantic North America for $945M cash, expected to close H1 2027.
Why this rating
Strong Q3 beat and guidance raise are favorable, but $945M SOFIE deal is 2.8% of market cap—material M&A but not transformational. Routine earnings outperformance for this scale company.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.